teva gains biosimilar momentum with u
Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, P...
Publisher
Israel
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, P...
Source route
Continue on tevapharm.com
Leave the platform to read the original full article on the publisher site.
Source: Teva Pharmaceuticals
Scope: Industry
Related coverage
More related coverage
Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia
The efzimfotase alfa (ALXN1850) Phase III clinical programme, designed to study a broad hypophosphat...
European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d)
European Commission approval: KYGEVVI® (doxecitine and doxribtimine) 2g/2g powder for oral solution...
Mar.02.2026CorporateAnnouncement on Changes of the Board of Directors and Corporate Officers
Osaka, Japan, March 2, 2026 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President an...
Press releaseMar 29, 2026Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta…
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study 1 40.7% o...